BioXcel Therapeutics, Inc.
BTAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $30 | $65 | $194 | $233 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $1 | $2 | $2 | $0 |
| Other Curr. Assets | $7 | $5 | $7 | $4 |
| Total Curr. Assets | $37 | $72 | $203 | $237 |
| Property Plant & Equip (Net) | $1 | $1 | $2 | $3 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $0 |
| Total NC Assets | $1 | $2 | $3 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $38 | $74 | $206 | $239 |
| Liabilities | – | – | – | – |
| Payables | $16 | $14 | $10 | $5 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $6 | $13 | $22 | $11 |
| Total Curr. Liab. | $22 | $27 | $33 | $17 |
| LT Debt | $103 | $101 | $94 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $7 | $2 | $2 | $0 |
| Total NC Liab. | $109 | $103 | $96 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $1 | $1 |
| Total Liabilities | $131 | $130 | $129 | $18 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$650 | -$591 | -$412 | -$246 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $557 | $534 | $488 | $467 |
| Total Equity | -$93 | -$57 | $77 | $222 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $38 | $74 | $206 | $239 |
| Net Debt | $73 | $36 | -$100 | -$232 |